(Reuters) – Celgene Corp (CELG.O) is in talks to buy Juno Therapeutics Inc (JUNO.O), the Wall Street Journal reported, citing sources familiar with the matter. (on.wsj.com/2EMlysO)
Shares of Juno, which has a market value of $5.57 billion, were up 36 percent at $62.50 in extended trading on Tuesday.
The WSJ report comes days after Celgene said it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance.
Reporting by Ankur Banerjee in Bengaluru